Immortalized PMF Cell Strain ZYXY-M2 for Drug Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for primary myelofibrosis (PMF) are limited, with no established cell strain for research, leading to a lack of understanding of its pathogenesis and limited drug screening options, resulting in a poor prognosis and high leukemia rate.
Innovation Solution
Development of a human primary myelofibrosis immortalized cell strain, ZYXY-M2, negative for JAK2, CALR, and MPL mutations but positive for ASXL1, TP53, FLT3, and IKZF1 mutations, which can be used to study PMF molecular characteristics, screen drugs, and develop therapeutic models.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If allogeneic hematopoietic stem cell transplantation (allo-HSCT) is performed to treat PMF, then survival time may be prolonged or cure achieved, but serious complications or death related to transplantation occur in at least 50% of patients
Solution Approach 1:
The patent creates an immortalized PMF cell line (PMF-01) that copies the molecular characteristics and pathogenic features of clinical PMF tumors. This cell line serves as a surrogate model for studying PMF pathogenesis and screening drugs, eliminating the need for high-risk allo-HSCT in research settings and reducing transplantation-related harms in clinical trials.
Solution Approach 2:
The immortalized PMF cell line enables preliminary drug screening and mechanism studies before clinical trials. Researchers can test potential therapies on the PMF-01 cell line to identify promising candidates, thereby reducing the risk and complications associated with subsequent clinical transplantation treatments.
2Ease of operation
If traditional drug treatment (hydroxyurea and ruxolitinib) is used for PMF, then clinical symptoms are improved, but anti-tumor activity is limited and bone marrow fibrosis cannot be reversed
Solution Approach 1:
The PMF-01 cell line replicates the molecular characteristics of clinical PMF tumors, including specific gene mutations and bone marrow fibrosis features. This copying enables researchers to screen for drugs with genuine anti-tumor activity that can reverse fibrosis, rather than merely suppressing symptoms as traditional drugs do.
Solution Approach 2:
The patent identifies and characterizes specific molecular parameters (gene mutations, protein expressions) in the PMF-01 cell line that differ from traditional PMF models. These parameter changes enable the development of targeted therapies that address the root cause of bone marrow fibrosis rather than just managing clinical symptoms.
3Loss of information
If no established cell strain is used for PMF research, then research on pathogenesis mechanisms is limited, but development of new therapeutic options is hindered
Solution Approach 1:
The PMF-01 immortalized cell line creates a faithful copy of clinical PMF tumors with preserved molecular characteristics, including JAK2, CALR, and MPL mutation statuses. This copying enables comprehensive pathogenesis research and high-throughput drug screening, simultaneously addressing both information loss and productivity limitations.
Solution Approach 2:
The PMF-01 cell line serves multiple functions: it can be used for studying pathogenesis mechanisms, screening novel drugs, evaluating drug efficacy, and investigating molecular characteristics. This multi-functionality eliminates the need for multiple different cell models, greatly enhancing both research understanding and drug development productivity.
4Adaptability or versatility
If JAK2 mutation-positive PMF patients are treated with current JAK inhibitors, then some response is achieved, but JAK2-negative patients (10%-15%) have no effective treatment options
Solution Approach 1:
The PMF-01 cell line preserves the authentic mutation profile of clinical PMF patients, including both JAK2-positive and JAK2-negative cases. This copying enables screening of novel therapeutic agents that may be effective across different molecular subtypes, thereby improving both response rate and treatment coverage for all PMF patients regardless of mutation status.
Solution Approach 2:
The patent characterizes multiple molecular parameters in the PMF-01 cell line beyond just JAK2 status, including CALR and MPL mutations. This comprehensive parameter analysis enables the development of targeted therapies that can adapt to different molecular subtypes, improving treatment versatility and reliability across the entire PMF patient population.
Data Source
AI summary
Providing a human primary myelofibrosis (PMF) cell strain, a construction method therefor and use thereof. The PMF cell strain is named as ZYXY-M2, and is deposited in China Center for Type Culture Collection (Wuhan University, Wuhan, China), with a preservation number of CCTCC NO: C202145. The present application is obtained by extracting and separating mononuclear cells from peripheral blood of a PMF patient and culturing in vitro for continuous natural passage. The leukemia cell strain is negative for JAK2, CALR, MPL mutation, positive for ASXL1, TP53, IKZF1, IDH1, FLT3 and TET1. The cell strain has good proliferation ability in vitro, and can be used as a cell material to study the pathogenesis of PMF and individualized treatment in vitro. Meanwhile, it can also be used to screen and evaluate drugs for in vitro and in vivo research of human PMF and guide clinical medication.